NCT07850466Not yet recruitingPhase 4
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
Short-term Effect of TRPTI Supplementation on GLP-1 and Related Metabolic Markers in Overweight or Obese Adults - a Double-blind, Randomised, Placebo-controlled, Two-arm Cross-over Study
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older). Researchers will compare TRPTI™ 150 mg to a matching placebo capsule to see if TRPTI™ produces a meaningful difference in GLP-1 response and associated metabolic and appetite-related markers over 8 hours. Participants will attend two 9-hour clinic visits (crossover design, with a minimum 6-day washout between visits).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 14 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- RDC Clinical Pty Ltd
- Diseases
- Obesity
- NCT number
- NCT07850466
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 20
- From 1 Oct 2026 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
- Active smokers, nicotine use or drug (prescription or illegal substances) abuse
Other illness
- Have a serious illness e.g., neurological disorders such as MS, kidney disease, liver disease or heart conditions
- Have an unstable illness e.g., thyroid gland dysfunction, uncontrolled mood disorders (e.g., depression, anxiety, bipolar)
- Diagnosed with any known metabolic or endocrine dysfunctions e.g., diabetes, NAFLD, hyperinsulinaemia, hypoglycaemia
- Allergic to any of the ingredients in active or placebo formula
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
Lab values
- History of any glucose or insulin regulation problem, including diabetes
- Use of any medication or supplements that may affect any metabolic pathway associated with satiety (e.g., GLP-1, GIP, glucagon), glucose or insulin
Other
- Significant change in diet in the past 1 month (e.g., removal of a food group or calorie restriction)
- Chronic past and/or current alcohol use (\>21 alcoholic drinks/week)
- Pregnant or lactating women
- Participants who are or who have participated in any other clinical trial during the past 1 month (excludes RDC clinical trials which are to be assessed on a case-by-case basis)
- Regular use within the past 4 weeks of supplements containing OEA and LipiSperse (TRPTITM)
Who the study is looking for
- Adults aged 30 years and older
- Generally healthy
- BMI 25.0-34.9 kg/m²
- Able to provide informed consent
- Agree to not participate in another clinical trial while enrolled in this trial
- Agree not to change current diet and/or exercise frequency or intensity during entire study period
- Females using a prescribed form of birth control (e.g., oral contraceptive)
- Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points
- Able to attend the clinic on all required days
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| RDC Clinical Coordinator of this site? Confirm its status | Fortitude Valley | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.